AAAAAA

   
Results: 1-10 |
Results: 10
Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents
Authors: Luo, Y Rockow-Magnone, SK Joseph, MK Bradner, J Butler, CC Tahir, SK Han, EKH Ng, SC Severin, JM Gubbins, EJ Reilly, RM Rueter, A Simmer, RL Holzman, TF Giranda, VL
Citation: Y. Luo et al., Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents, ANTICANC R, 21(1A), 2001, pp. 23-28
Identification and characterization of A-105972, an antineoplastic agent
Authors: Wu-Wong, JR Alder, JD Alder, L Burns, DJ Han, EKH Credo, B Tahir, SK Dayton, BD Ewing, PJ Chiou, WJ
Citation: Jr. Wu-wong et al., Identification and characterization of A-105972, an antineoplastic agent, CANCER RES, 61(4), 2001, pp. 1486-1492
A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors
Authors: Tahir, SK Han, EKH Credo, B Jae, HS Pietenpol, JA Scatena, CD Wu-Wong, JSR Frost, D Sham, H Rosenberg, SH Ng, SC
Citation: Sk. Tahir et al., A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors, CANCER RES, 61(14), 2001, pp. 5480-5485
Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth
Authors: Chen, J Wu, W Tahir, SK Kroeger, PE Rosenberg, SH Cowsert, LM Bennett, F Krajewski, S Krajewska, M Welsh, K Reed, JC Ng, SC
Citation: J. Chen et al., Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth, NEOPLASIA, 2(3), 2000, pp. 235-241
Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue
Authors: Tahir, SK Gu, WZ Zhang, HC Leal, J Lee, JY Kovar, P Saeed, B Cherian, SP Devine, E Cohen, J Warner, R Wang, YC Stout, D Arendsen, DL Rosenberg, S Ng, SC
Citation: Sk. Tahir et al., Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue, EUR J CANC, 36(9), 2000, pp. 1161-1170
Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines
Authors: Han, EKH Gehrke, L Tahir, SK Credo, RB Cherian, SP Sham, H Rosenberg, SH Ng, SC
Citation: Ekh. Han et al., Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines, EUR J CANC, 36(12), 2000, pp. 1565-1571
Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin
Authors: Tahir, SK Kovar, P Rosenberg, SH Ng, SC
Citation: Sk. Tahir et al., Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin, BIOTECHNIQU, 29(1), 2000, pp. 156-160
Modulation of paolitaxel resistance by annexin IV in human cancer cell lines
Authors: Han, EKH Tahir, SK Cherian, SP Collins, N Ng, SC
Citation: Ekh. Han et al., Modulation of paolitaxel resistance by annexin IV in human cancer cell lines, BR J CANC, 83(1), 2000, pp. 83-88
Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo
Authors: Gu, WZ Tahir, SK Wang, YC Zhang, HC Cherian, SP O'Connor, S Leal, JA Rosenberg, SH Ng, SC
Citation: Wz. Gu et al., Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo, EUR J CANC, 35(9), 1999, pp. 1394-1401
Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines
Authors: Gu, WZ Chen, ZH Tahir, SK Rosenberg, SH Ng, SC
Citation: Wz. Gu et al., Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines, ANTI-CANC D, 10(10), 1999, pp. 895-901
Risultati: 1-10 |